Search results for "Combined treatment"

showing 10 items of 23 documents

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Efficacy and foliar absorption of flupyrsulfuron-methyl and prosulfocarb applied alone or in mixture on Lolium multiflorum and wheat

2001

Des melanges de flupyrsulfuron-methyle et de prosulfocarbe concus pour ameliorer la lutte contre Lolium multiflorum Lam. dans le ble (Triticum aestivum L.) ont ete etudies grâce a des essais biologiques sur plantes entieres et a des etudes de penetration foliaire. Dans les essais biologiques, le flupyrsulfuron-methyle et le prosulfocarbe etaient appliques a 6-7 doses, seuls ou en melange dans les rapports 1:400, 1:40 et 1:4 (p/p). Les courbes de reponse etaient ajustees au moyen de modeles logistiques et l'action conjuguee etait evaluee par la methode des isoboles. Dans les essais biologiques conduits en serre sur L. multiflorum, l'action conjuguee des melanges montrait une additivite de do…

2. Zero hunger[SDV.SA]Life Sciences [q-bio]/Agricultural sciences[SDV.SA] Life Sciences [q-bio]/Agricultural sciencesbiologyChemistryFLUPYRSULFURON-METHYL04 agricultural and veterinary sciencesLolium multiflorum010501 environmental sciencesbiology.organism_classification01 natural sciencesMolecular biologyJoint actionCombined treatmentFlupyrsulfuronBotany040103 agronomy & agriculture0401 agriculture forestry and fisheriesAgronomy and Crop ScienceProsulfocarbComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciences
researchProduct

Interactions between artemisinin derivatives and P-glycoprotein

2019

Abstract Background Artemisinin was isolated and identified in 1972, which was the starting point for a new era in antimalarial drug therapy. Furthermore, numerous studies have demonstrated that artemisinin and its derivatives exhibit considerable anticancer activity both in vitro, in vivo, and even in clinical Phase I/II trials. P-glycoprotein (P-gp) mediated multi-drug resistance (MDR) is one of the most serious causes of chemotherapy failure in cancer treatment. Interestingly, many artemisinin derivatives exhibit excellent ability to overcome P-gp mediated MDR and even show collateral sensitivity against MDR cancer cells. Furthermore, some artemisinin derivatives show P-gp-mediated MDR r…

ATP Binding Cassette Transporter Subfamily BPharmaceutical ScienceAntineoplastic AgentsPharmacology03 medical and health sciences0302 clinical medicineCombined treatmentIn vivoNeoplasmsparasitic diseasesDrug DiscoverymedicineHumansATP Binding Cassette Transporter Subfamily B Member 1Artemisinin030304 developmental biologyP-glycoproteinPharmacology0303 health sciencesbiologyChemistryArtemisininsDrug Resistance MultipleCancer treatmentMultiple drug resistanceComplementary and alternative medicine030220 oncology & carcinogenesisCancer cellbiology.proteinMolecular Medicinemedicine.drugPhytomedicine
researchProduct

Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)

2019

BACKGROUND Hidradenitis suppurativa is a chronic inflammatory disease with high burden. Treatment options are often unsatisfactory. We assessed the effect of a combination therapy of intense pulsed light (IPL) and radiofrequency (RF). METHODS The explorative study included 47 patients and was performed as a prospective, monocentric, randomized, three-arm parallel-group design trial with a prior 12 weeks observation period. Treatment arms were IPL and RF monotherapies or IPL + RF combination therapy. After 12 weeks, all patients received IPL + RF for additional 12 weeks (cross-over). Primary endpoint was the change in active lesion numbers, secondary endpoint the change in Dermatology Qualit…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentDermatologyIntense pulsed lightChronic inflammatory diseaseLesionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCombined treatmentmedicineClinical endpointHumansHidradenitis suppurativaProspective Studies030203 arthritis & rheumatologybusiness.industryIntense Pulsed Light TherapyTreatment optionsMiddle AgedRadiofrequency Therapymedicine.diseaseCombined Modality TherapyDermatologyHidradenitis SuppurativaTreatment OutcomeQuality of LifeFemalesense organsmedicine.symptombusinessJournal of Dermatological Treatment
researchProduct

Laser Doppler flux and tissue oxygenation of experimental tumours upon local hyperthermia and/or hyperglycaemia

1992

Laser Doppler fluxmetry and oxygen partial pressure (pO2) histography have been applied to investigate the acute effects of hyperthermia (HT) and/or hyperglycaemia (HG) on microcirculatory function and tissue oxygenation of subcutaneous rat tumours growing on the dorsum of the hind foot. The experiments were performed to test whether, and to what extent, the two adjunct treatment modalities applied alone or in combination can modify these therapeutically relevant parameters. Local HT was performed in a saline bath (44 degrees C) for 2 h; HG was induced by i.v. infusion of 40% glucose solution for 2.5 h (blood glucose levels: 35-40 mM during heating). Laser Doppler flux (LDF) in superficial …

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyRadiosensitizerPathologymedicine.medical_treatmentBiologyLaser doppler fluxOxygen ConsumptionCombined treatmentInternal medicinemedicineAnimalsSalineGlucose tolerance testmedicine.diagnostic_testLasersRats Inbred StrainsHyperthermia InducedNeoplasms ExperimentalGeneral MedicineOxygenationmedicine.diseaseRatsTissue oxygenationOncologyCardiologyFemaleJournal of Cancer Research and Clinical Oncology
researchProduct

Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.

2013

Notch is a family of transmembrane receptors whose activation through proteolytic cleavage by γ-secretase targets genes which participate in cell development, differentiation and tumorigenesis. Notch signaling is constitutively activated in various cancers, including breast cancer and its upregulation is usually related with poor clinical outcomes. Therefore, targeting Notch signaling with γ-secretase inhibitors (GSIs) is considered a promising strategy for cancer treatment. We report that the γ-secretase inhibitor-I (GSI-I) sensitizes human breast cancer cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The antiproliferative GSI-I/TRAIL synergi…

Cancer ResearchNotch signaling pathwayApoptosisBreast NeoplasmsBiologymedicine.disease_causeTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationGenes junSettore BIO/10 - BiochimicaSurvivinmedicineHumansTranscription factorReceptors NotchCell DifferentiationCell biologyGene Expression Regulation NeoplasticReceptors TNF-Related Apoptosis-Inducing LigandOncologyApoptosisCancer cellMCF-7 CellsFemalenotch signaling γ-secretase inhibitor-I/TRAIL combined treatment apoptosis breast cancer cells AP-1Signal transductionAmyloid Precursor Protein SecretasesCarcinogenesisSignal TransductionInternational journal of oncology
researchProduct

Isovaleraldehyde degradation using UV photocatalytic and dielectric barrier discharge reactors, and their combinations

2015

International audience; The abatement of isovaleraldehyde present in air was carried out in UV photocatalytic and dielectric barrier discharge reactors (and their combinations) for concentrations up to 150 mg C m−3 and air flow rates ranging from 4 to 10 m3 h−1. A kinetic study was performed following a Langmuir–Hinshelwood model. Photocatalytic treatment of an isovaleraldehyde and isovaleric acid mixture showed a clear inhibition of isovaleric acid abatement in presence of isovaleraldehyde. Dielectric barrier discharge treatment of isovaleraldehyde showed an increase of removal efficiency with applied voltage and a decrease with air flow rate and inlet concentration. Moreover, introduction…

ChromatographyChemistryGeneral Chemical EngineeringInorganic chemistryDielectric barrier discharge treatmentGeneral Physics and AstronomyGeneral ChemistryDielectric barrier dischargeQuímicaUV photocatalytic reactor6. Clean waterIsovaleraldehydeCatalysischemistry.chemical_compoundCombined treatment[CHIM.GENI]Chemical Sciences/Chemical engineeringCoupled systemAir flow ratePhotocatalysisDegradation (geology)Hybrid reactorHybrid reactorEnginyeria ambientalVOC removal
researchProduct

Combined treatment of epidermodysplasia verruciformis with etretinate and α-interferon*

1992

Epidermodysplasia verruciformis (EV) is an uncommon cutaneous disease in which a focal and genetically determined immunological impairment is associated with chronic human papilloma virus (HPV) infection. In sun-exposed areas, when an oncogenic HPV type is the agent, skin cancer may occur. The treatment of EV is difficult and often unsatisfactory; etretinate has been reported in some instances as effective in improving lesions. We report a typical case of EV with pityriasis versicolor-like lesions on the trunk and many flat, erythematous wart-like lesions on the face, dorsal areas of the hands and legs. We performed a treatment with etretinate (1 mg/kg/day for 6 weeks) and subsequently with…

Dorsummedicine.medical_specialtyα interferonHpv typesbusiness.industryEtretinateDermatologyEpidermodysplasia verruciformisPityriasismedicine.diseaseDermatologyInfectious DiseasesCombined treatmentMedicineSkin cancerbusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Comparison of toxic effects on CHO-KL and VERO cells after individual and combined treatment with Fusarium mycotoxins, beauvericin, deoxynivalenol an…

2009

FusariumbiologyToxinGeneral MedicineToxicologybiology.organism_classificationmedicine.disease_causeBeauvericinMicrobiologychemistry.chemical_compoundCombined treatmentchemistrymedicineVero cellMycotoxinToxicology Letters
researchProduct

Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie e…

2011

Resume Objectif de l’etude Etudier l’apport de la chimioradiotherapie concomitante suivie de chimiotherapie dans le cancer pancreatique localement evolue, par rapport a la chimiotherapie seule. Patients et methodes Cent dix-neuf patients atteints d’un cancer pancreatique localement evolue, avec indice de performance de 0 a 2 selon l’Organisation mondiale de la sante, ont ete randomises entre une chimioradiotherapie concomitante d’induction (60 Gy, 2 Gy/fraction ; perfusion concomitante de 5-fluoro-uracile de 300 mg/m2 par jour, de j1 a j5 pendant six semaines ; cisplatine, 20 mg/m2 par jour, de j1 a j5 pendant la premiere et la cinquieme semaines) et une chimiotherapie d’induction par gemci…

Gynecology0303 health sciencesmedicine.medical_specialtybusiness.industryGemcitabine3. Good health03 medical and health sciences0302 clinical medicineCombined treatmentOncology030220 oncology & carcinogenesisOverall survivalmedicineRadiology Nuclear Medicine and imagingbusinessINDUCTION TREATMENT030304 developmental biologymedicine.drugCancer/Radiothérapie
researchProduct